ReviewPharmaceutical research2016
Emergence of 3D Printed Dosage Forms: Opportunities and Challenges.
Review in Pharmaceutical research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 131 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
131 citing papers in PubMed, 535 citations in OpenAlex.
- 3D bioprinting technologies and biomaterial-based scaffolds for wound healing: Insights into decellularized tissue-derived bioinks.Regenerative therapy · 2026Review
- Rheology-Informed Working Thresholds for HME/FDM Processability in a PVA-Sorbitol-Paracetamol Model System.Pharmaceutics · 2026Article
- Iron Oxide Nanoparticles Integrated in 3D-Printed Dosage Forms for Advanced Iron Supplementation.ACS nanoscience Au · 2026Article
- Network pharmacology and bioinformatics analysis-based strategy for exploring the mechanisms of luteolin in the treatment of five types of cancer: A retrospective computational study.The Journal of international medical research · 2026Article
- Evaluation of the Applicability of a 3D-Printed Inert Minitablet Core as a Carrier for Modified-Release Drug Delivery System.Pharmaceutics · 2026Article
- Gelatin-based porous scaffolds: design concepts, production, and applications in precision regenerative medicine.Materials today. Bio · 2026Review
- Three-Dimensional Printing for Precision and Personalized Patient Care: A New Paradigm for Pharmacy Practice?Pharmaceutics · 2026Review
- Effect of Process and Formulation Variables on Quality, Stability, and Taste of Lamivudine Printlets Manufactured by Binder Jetting 3D Printing Method.AAPS PharmSciTech · 2026Article
- Structured engineering of self-emulsifying drug delivery systems (SEDDS)International journal of pharmaceutics: X · 2025Review
- Thermal Stability of Dexamethasone-Evaluation with Regard to Modern Medicinal and Pharmaceutical 3D-Printing Applications.Molecules (Basel, Switzerland) · 2025Article
- Three-Dimensional Printing in Paediatrics: Innovative Technology for Manufacturing Patient-Centred Drug Delivery Systems.Pharmaceutics · 2025Review
- A framework for conducting clinical trials involving 3D printing of medicines at the point-of-care.Drug delivery and translational research · 2025Review
- Article
- Behavior of Aqueous Medicated Inks on Porous Tablet Surfaces.Pharmaceutics · 2025Article
- 3D Printing in Oral Drug Delivery: Technologies, Clinical Applications and Future Perspectives in Precision Medicine.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Automated 3D Printing-Based Non-Sterile Compounding Technology for Pediatric Corticosteroid Dosage Forms in a Health System Pharmacy Setting.Pharmaceutics · 2025Article
- Fast shape memory function and personalized PLTMC/SIM/MBG composite scaffold for bone regeneration.Materials today. Bio · 2025Article
- Fabrication of 3D Printed Microneedle Patch for the Simultaneous Delivery and Detection of Melatonin from Interstitial Fluid.AAPS PharmSciTech · 2025Article
- Three-Dimensional Surgical Guides in Orthodontics: The Present and the Future.Dentistry journal · 2025Review
- Review
71 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent introduction of the first FDA approved 3D-printed drug has fuelled interest in 3D printing technology, which is set to revolutionize healthcare. Since its initial use, this rapid prototyping (RP) technology has evolved to such an extent that it is currently being used in a wide range of applications including in tissue engineering, dentistry, construction, automotive and aerospace. However, in the pharmaceutical industry this technology is still in its infancy and its potential yet to be fully explored. This paper presents various 3D printing technologies such as stereolithographic, powder based, selective laser sintering, fused deposition modelling and semi-solid extrusion 3D printing. It also provides a comprehensive review of previous attempts at using 3D printing technologies on the manufacturing dosage forms with a particular focus on oral tablets. Their advantages particularly with adaptability in the pharmaceutical field have been highlighted, which enables the preparation of dosage forms with complex designs and geometries, multiple actives and tailored release profiles. An insight into the technical challenges facing the different 3D printing technologies such as the formulation and processing parameters is provided. Light is also shed on the different regulatory challenges that need to be overcome for 3D printing to fulfil its real potential in the pharmaceutical industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.